Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1093/ckj/sfv139 http://scihub22266oqcxt.onion/10.1093/ckj/sfv139 C4792614!4792614!26985375     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=26985375&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Clin+Kidney+J 2016 ; 9 (2): 239-44 Nephropedia Template TP {{tp|p=26985375|t=2016. Minimal change disease onset observed after bevacizumab administration |pdf=|usr=}}{{26985375}} gab.com Text Minimal change disease onset observed after bevacizumab administration JO: Clin Kidney J http://www.kidney.de/pget.php?&tw=1&pmid=26985375 #FOAvip This is a report of a patient with minimal change disease (MCD) onset after bevacizumab administration. A 72-year-old man with inoperable Grade 3 astrocytoma was treated with a combination of temozolomide and the vascular endothelial growth factor monoclonal antibody bevacizumab. After two biweekly treatments, he developed nephrotic syndrome. Despite cessation of bevacizumab, his renal function deteriorated and a renal biopsy disclosed MCD. Thereafter, he was started on high-dose oral prednisone and renal function immediately improved. Within weeks, the nephrotic syndrome resolved. Although rare, biologic agents can cause various glomerulopathies that can have important therapeutic implications. MCD should be considered in patients who develop nephrotic syndrome while exposed to antiangiogenic agents. Twit Text FOAVip Minimal change disease onset observed after bevacizumab administration ????Clin Kidney J http://www.kidney.de/pget.php?&tw=1&pmid=26985375 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26985375 #FOAvip English Wikipedia <ref>{{Cite pmid|26985375}}</ref> Minimal change disease onset observed after bevacizumab administration #MMPMID26985375 Hanna RM; Lopez E; Wilson J; Barathan S; Cohen AH Clin Kidney J 2016[Apr]; 9 (2): 239-44 PMID26985375show ga This is a report of a patient with minimal change disease (MCD) onset after bevacizumab administration. A 72-year-old man with inoperable Grade 3 astrocytoma was treated with a combination of temozolomide and the vascular endothelial growth factor monoclonal antibody bevacizumab. After two biweekly treatments, he developed nephrotic syndrome. Despite cessation of bevacizumab, his renal function deteriorated and a renal biopsy disclosed MCD. Thereafter, he was started on high-dose oral prednisone and renal function immediately improved. Within weeks, the nephrotic syndrome resolved. Although rare, biologic agents can cause various glomerulopathies that can have important therapeutic implications. MCD should be considered in patients who develop nephrotic syndrome while exposed to antiangiogenic agents. äMinimal change disease onset observed after bevacizumab administration(epmc).pdf DeepDyve Pubget Overpricing